HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: hemophilia A without factor VIII inhibitors, or, hemophilia B without factor IX inhibitors. HYMPAVZI is a tissue factor pathway inhibitor antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:, hemophilia A without factor VIII inhibitors, or, hemophilia B without factor IX inhibitors.